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Structured Abstract and Key Words 93 
 94 
Objective: To evaluate whether pre-treatment DHEA supplementation would improve 95 
ovarian response markers, ovarian response to standard low dose gonadotrophin stimulation 96 
and IVF outcomes in poor responders  97 
 98 
Design: Randomized double-blinded placebo-controlled study 99 
 100 
Setting: Tertiary reproductive medicine unit  101 
 102 
Patients: 32 women with anticipated poor ovarian response  103 
 104 
Interventions: Eligible subjects were randomized into the DHEA group (n=16) who 105 
received DHEA (GNC, 25mg three times a day) or the placebo group (n=16) who received 106 
placebo starting from at least 12 weeks before the scheduled IVF treatment according to a 107 
computer-generated randomization list. Monthly ovarian response markers including antral 108 
follicle count (AFC), serum anti-Mullerian hormone (AMH) and follicle stimulating 109 
hormone (FSH) levels, ovarian response to a standard dose of gonadotrophin stimulation at 110 
week 8 and IVF outcomes were compared.  111 
 112 
Main outcome measures: Primary outcome was AFC after 12 weeks of intervention 113 
 114 
Results: DHEA supplementation resulted in significantly higher serum DHEA-S, free 115 
androgen index and follicular DHEA-S levels. No significant differences in ovarian 116 
 5 
response markers (AFC, AMH and FSH), ovarian response to standard dose gonadotrophin 117 
stimulation and IVF outcomes were found between the two groups.  118 
 119 
Conclusions: No significant improvement in ovarian response markers, ovarian response to 120 
standard dose gonadotrophin stimulation and IVF outcomes can be found in poor 121 
responders receiving pre-treatment DHEA.  122 
 123 
 124 
Clinical Trial Registration Number: HKCTR-1149 (www.hkclinicaltrials.com) and 125 
NCT01915186 (www.clincialtrials.org) 126 
 127 
Keywords: DHEA, in-vitro fertilization, ovarian response markers, poor responders 128 
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INTRODUCTION 130 
 131 
Dehydroepiandrosterone (DHEA) is an endogenous steroid produced mainly in the zona 132 
reticularis of adrenal cortex and ovarian theca cells in women. Androgens have been 133 
implicated in ovarian follicular steroidogenesis and is believed to increase follicular 134 
insulin-like growth factor-1 (IGF-1) that promotes folliculogenesis (1), potentiates the 135 
effects of gonadotropin (2) and reduces follicular arrest (3).  136 
 137 
Previous observational studies have reported preliminary success in using DHEA in poor 138 
responders leading to improved ovarian response, increased oocyte yield, improved embryo 139 
quality, reduced miscarriage rates, as well as higher pregnancy rates following assisted 140 
reproductive treatments (2, 4-7). A recent meta-analysis including three randomized 141 
controlled trials (RCTs) (8-10) using transdermal testosterone and one RCT using DHEA 142 
(11) has shown an increased ongoing pregnancy /live-birth rates [RR 2.08; 95% confidence 143 
interval (1.10,3.93); p=0.002] when adjuvant androgen (DHEA or testosterone) 144 
pretreatments were given to poor responders (12). A worldwide survey conducted in 2010 145 
revealed that over a quarter (26%) of IVF clinicians added DHEA as an adjuvant to IVF 146 
treatment protocols in poor responders (13). Even in women with primary ovarian 147 
insufficiency (POI), our group has previously demonstrated improvements in antral follicle 148 
count (AFC), ovarian volume and follicular activity after DHEA supplementation in an 149 
RCT (14).  150 
 151 
Despite the wider use of DHEA in poor responders, there are still considerably diverse 152 
views among many clinicians. Most of the published studies were based on retrospective 153 
and/or observational data, and the results were not free from bias. The aim of this study is 154 
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to assess the effect of DHEA on ovarian response markers, ovarian response to standard 155 
gonadotrophin stimulation and the number of oocytes obtained in poor responders in an 156 
RCT setting.  157 
 158 
MATERIALS AND METHODS 159 
 160 
Study design and protocol 161 
Consecutive women attending the Subfertility Clinic at the Department of Obstetrics and 162 
Gynaecology, University of Hong Kong who were indicated for IVF treatment were 163 
screened and recruited.  164 
 165 
Inclusion criteria included: (a) age =<40 years; (b) subfertility > 1 year; (c) expected poor 166 
ovarian response defined as AFC < 5. Patients were excluded if they had (a) history of 167 
ovarian cystectomy or oophorectomy; (b) received cytotoxic chemotherapy; (c) received 168 
pelvic irradiation or (d) history of taking testosterone or DHEA supplement.  169 
 170 
The study had been approved by the Institutional Review Board of the University of Hong 171 
Kong/Hospital Authority Hong Kong West Cluster and was registered under Hong Kong 172 
Clinical Trial Center (HKCTR-1149) and Clinicaltrials.gov (NCT01915186). All women 173 
were fully counseled and written consents were obtained.   174 
 175 
Baseline assessments were performed on the second day of the menstrual cycle 12 weeks 176 
prior to the scheduled IVF treatment. Ovarian response markers including AFC, serum anti-177 
Mullerian hormone (AMH) and follicle stimulating hormone (FSH) levels were measured. 178 
Serum estradiol (E2), testosterone, DHEA-S, sex hormone binding globulin (SHBG), 179 
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insulin-like growth factor-1 (IGF-1), complete blood picture and liver enzymes were also 180 
checked.  181 
 182 
Assignment and masking 183 
Women were randomized in 1:1 ratio according to a computer-generated randomization list 184 
generated by a research nurse not involved in the subjects’ clinical management and were 185 
allocated in sealed, opaque, sequentially number envelopes. The hospital pharmacy 186 
packaged the DHEA and identical placebo capsules according to the randomization list and 187 
labeled the drug packs with subject numbers only. Physicians, research nurses involved and 188 
study subjects were all blinded to the assignment.  189 
 190 
Treatment and Monitoring 191 
Pretreatment and monitoring 192 
Either DHEA (GNC LiveWell™) capsule at 25mg three times a day (i.e. 75 mg per day) or 193 
matching placebo capsules were started after baseline investigations. Subjects were 194 
followed up at 4-weekly intervals at week 0, week 4, week 8, and week 12. Transvaginal 195 
scans were performed by gynaecologists experienced in pelvic scanning using a 7 MHz 196 
vaginal probe (Voluson 730®, GE Healthcare, Wisconsin, USA) to determine AFC (2-9 197 
mm) in both ovaries. The intra-observer coefficient of variation (CV) for AFC was 7%. 198 
Blood was collected for serum AMH, FSH, E2, testosterone, DHEA-S, SHBG, IGF-1, 199 
complete blood picture and liver function.  200 
 201 
Standard low dose ovarian stimulation 202 
At week 8, low dose gonadotrophin stimulation using 75 IU human menopausal 203 
gonadotrophin (HMG, Menogon®, Ferring Pharmaceuticals) was given on the 2nd - 8th 204 
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day as a standardized test for ovarian response. Ovarian response was assessed on the 10th 205 
day by the number of follicle(s) >10mm and serum E2 levels (15).  206 
 207 
IVF treatment  208 
At week 12, subjects were treated with ovarian stimulation under the fixed antagonist 209 
protocol. HMG injections were started at 450 IU for 2 days followed by 300 IU daily. 210 
Ovarian response was monitored by serial transvaginal scanning with or without hormonal 211 
monitoring. Further dosage adjustments were based on the ovarian response. When the 212 
leading follicle was >/=18mm, human chorionic gonadotrophin (hCG, Pregnyl [Organon, 213 
Oss, the Netherlands]) 10,000 IU was given intramuscularly to trigger final maturation of 214 
oocytes. Cycles were cancelled if the follicles remained <10mm after 14 days of 215 
stimulation. Transvaginal ultrasound guided oocyte retrievals (TUGOR) were scheduled 36 216 
hours later. A maximum of two embryos were transferred two days after TUGOR. Excess 217 
good quality embryos were frozen for subsequent transfer.  218 
  219 
Serum samples were stored at -200C until assayed as a whole batch.  Follicular fluid was 220 
collected from dominant follicles during oocyte retrievals. Samples were assayed for AMH, 221 
FSH, E2, progesterone, DHEA-S, testosterone and IGF-1. Serum and follicular AMH 222 
levels were measured using AMH Gen II ELISA (Beckman Coulter); IGF-1 levels were 223 
measured using Quantikine ELISA human IGF-1 (R&D System), whereas E2, progesterone, 224 
testosterone, DHEA-S and SHBG were measured using Beckman Coulter Access 2 225 
Immunoassay system.  226 
 227 
The intra-assay CVs were 3.4-5.4% for AMH, 3.5-4.3% for IGF-1, 12-21% for E2, 7.51-228 
9.57% for progesterone, 1.67-3.93% for testosterone, 1.6-8.3% for DHEA-S and 4.5-4.8% 229 
for SHBG. The inter-assay CV were 4.0-5.6% for AMH, 7.5-8.1% for IGF-1, 12 – 21% for 230 
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estradiol, 6.11 – 11.19% for progesterone, 4.22-7.08% for testosterone, 3.7-11.3% for 231 
DHEA-S and 5.2-5.5% for SHBG. Detection limits were 0.08-22.5 ng/ml for AMH, 0.007-232 
6 ng/ml for IGF-1, 73–17621pmol/L for E2, 0.25–127.2nmol/L for progesterone, 0.1-16 233 
ng/ml for testosterone, 2-1000 μg/dL for DHEA-S and 0.33-200 nmol/L for SHBG.  234 
 235 
 236 
Statistical analysis 237 
 238 
AFC at week 12 was used as the primary outcome measure. We aimed at assessing any 239 
improvement in functional ovarian reserve as the first step. AFC was chosen since its 240 
predictive performance for functional ovarian reserve and ovarian response has been shown 241 
to be significantly better than that of basal FSH(16) and comparable to the use AMH(17, 18) 242 
or multivariate models(18, 19) in meta-analysis. 243 
 244 
Secondary outcome measures included changes in FSH and AMH; serum and follicular 245 
hormonal profiles (E2, testosterone, DHEA-S, SHBG and IGF-1); post stimulation E2 and 246 
number of follicles > 10mm; and the number of oocytes obtained.  247 
 248 
Based on our own database for anticipated poor responders (AFC <5) undergoing IVF 249 
treatment, the mean AFC was 3.10 with a standard deviation of 1.05 (unpublished data). 250 
Assuming an increase of AFC by 2.0 being clinically significant (i.e. with the resultant 251 
AFC of > 5 and beyond our current definition of anticipated poor responders), 6 subjects in 252 
each arm would be required for a test significance of 0.05 and power of 0.8. Considering 253 
possible dropouts, we aim at recruiting 8 patients in each arm with a total of 16 patients. 16 254 
patients undergoing their first IVF treatment cycle and 16 patients undergoing their 255 
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subsequent treatment cycle were recruited. Continuous variables are expressed as median 256 
(25th to 75th centiles). Statistical comparisons were carried out with the intention to treat by 257 
Mann-Whitney-U test, Chi-square test and Fisher’s exact test where appropriate using the 258 
Statistical Program for Social Sciences (SPSS Inc., Version 21.0, Chicago, U.S.A.). A two-259 
sided P < 0.05 was taken as statistically significant. 260 
 261 
RESULTS 262 
 263 
Participant flow   264 
Between August 2010 and August 2012, a total of 32 subjects were recruited with eighteen 265 
women undergoing their first IVF cycles and fourteen undergoing their subsequent 266 
treatment cycles (Supplemental Figure 1 – Consort 2010 Flow Diagram).  267 
 268 
Baseline characteristics 269 
Baseline characteristics of the DHEA and placebo groups including age of women, body 270 
mass index, duration, type and causes of subfertility and ovarian response markers are 271 
represented in Table 1. 272  273 
Primary outcomes 274  275 
No significant difference in median AFC had been detected between the DHEA and 276 
placebo groups throughout the study period (Figure 1). There was no significant 277 
improvement in AFC in DHEA group after 12 weeks of supplementation compared to its 278 
baseline [3.5 (1.75 – 4.25) vs 4 (3-4), p=0.436]. 279 
 280 
Secondary outcomes 281 
 282 
Serum hormonal profiles  283 
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Similar to AFC, serum FSH and AMH levels were comparable between the two groups 284 
throughout the study period (Fig 1). 285 
 286 
Serum testosterone and DHEA-S levels were significantly higher in DHEA group after 287 
DHEA supplementation in Week 4, 8 and 12 compared to the placebo group. Serum SHBG 288 
levels were significantly lower, leading to significantly higher free androgen indexes (FAI) 289 
in the DHEA group (Fig 1).  290 
 291 
No significant difference in serum IGF-1 after 12 weeks was detected between DHEA 292 
group [88.0 (67.6 – 126.2) ng/ml] and placebo group [78.0 (47.5 – 113.2) ng/ml]. 293 
 294 
Response to a standard low dose gonadotrophin stimulation 295 
Higher post-stimulation E2 level was observed after the standard dose ovarian stimulation 296 
with HMG at 75 IU daily for 7 days in the DHEA group, although it did not reach statistical 297 
significance [1076 (888–1232) vs 501 (216 - 1116) pmol/L, p=0.252]. Number of follicle(s) 298 
larger than 10mm was similar [1 (1-2) vs 1 (0-2), p=0.290]. 299 
 300 
IVF cycle characteristics 301 
Shorter duration [median 10 (9 - 12.2) vs 12 (8 - 15) days, p=0.114] and lower dose [2475 302 
(2475 - 3206) vs 3150 (2925 - 4425) IU, p=0.069] of gonadotrophin use were detected in 303 
the DHEA group, although they did not reach statistical significance. The number of 304 
follicles at various sizes and number of oocytes obtained were similar but there were higher 305 
numbers of fertilized, cleaved, transferred and top quality embryos – TQE (defined as 4-306 
celled grade 1 or 2 on day 2 - i.e. blastomeres of equal size with no or minor fragmentation 307 
(20)) in the DHEA group, although again, they failed to reach statistical significance (Table 308 
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2). Three patients (18.6%) in DHEA group had cycle cancellation due to premature 309 
ovulation; while two patients (12.5%) in the placebo group had cycle cancelled, one due to 310 
premature ovulation and one due to absence of ovarian response despite prolonged ovarian 311 
stimulation.  312 
 313 
Follicular fluid hormonal profiles 314 
Median follicular DHEA-S level was significantly higher in the DHEA group. Follicular 315 
AMH was also higher in DHEA group, although it did not reach statistical significance. 316 
Follicular estradiol, progesterone and IGF-1 levels were similar for the two groups (Fig 2).   317 
 318 
Pregnancy Outcomes 319 
No significant difference in the clinical pregnancy (18.8% vs 25.0%, p = 0.380), ongoing 320 
pregnancy (18.8% vs 12.5%, p = 0.326), live birth (12.5% vs 12.5%, p = 1.000) and 321 
miscarriage (0 vs 12.5%, p=0.326) rates had been observed between DHEA and placebo 322 
groups. There was no multiple pregnancy in either group. 323 
 324 
 325 
Subgroup analyses  326 
Subgroup analyses were performed after stratifying subjects into those undergoing their 327 
first IVF cycles (n=18) or subsequent IVF cycles (n=14). There were no significant 328 
differences in AFC, AMH and FSH, gonadotrophin requirements and pregnancy rates 329 
throughout the study period (data not shown).  330 
 331 
Subgroup analyses were also performed by dividing the subjects into halves according to 332 
their serum and follicular DHEA-S levels. Women in the subgroup with higher serum 333 
DHEA-S (cut-off at 220μg/dL) had significantly higher serum E2 level on the day of HCG 334 
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trigger [5272 (2902 - 7658) vs 3020 (989 - 4132) pmol/L, p=0.033]. Women having higher 335 
follicular DHEA-S (cut-off at 180μg/dL) had a significantly higher number of good quality 336 
embryos [1 (0-2) vs 0 (0-0.25), p = 0.013]. No significant differences in all parameters 337 
could be found in regards to follicular testosterone (cut-off at 5.5 ng/ml) and serum 338 
testosterone (cut-off at 1.0 ng/ml) levels or FAI (cut-off at 11). 339 
 340 
Side effects 341 
No major adverse effects were reported during the study period. One patient from DHEA 342 
group discontinued the intervention before week 4 complaining of increased acne. Monthly 343 
monitoring of liver function and complete blood picture did not reveal any derangement.  344 
 345 
 346 
 347 
  348 
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DISCUSSION 349 
 350 
In our present study, we did not find any significant improvement in the functional ovarian 351 
reserve after 12 weeks of DHEA supplementation, using AFC as the surrogate marker.  352 
 353 
Management of poor responders remains one of the biggest challenges in fertility treatment. 354 
Numerous studies have been performed to assess different stimulation protocols and 355 
adjuvant therapies to improve ovarian response, but the latest Cochrane review concluded 356 
that there is insufficient evidence to support the routine use of any particular intervention 357 
(21).  358 
 359 
Accumulation of androgens in the micro-milieu of primate ovaries had been shown to play 360 
a critical role in early follicular development and granulosa cell proliferation (22, 23). 361 
Androgens promote recruitment and initiation of primordial follicle growth and induce 362 
significant increase in the number of primary, preantral and antral follicles through up-363 
regulation of IGF-1 (1, 23); up-regulate FSH receptors expression in granulosa cells to 364 
potentiate the effect of FSH (1, 22, 24, 25); and exert paracrine regulation on follicular 365 
maturation and reduce follicular atresia (1, 24). At the same time, lack of androgen has 366 
been shown to reduce the number of antral follicles and ovulated oocytes (26) as well as 367 
accelerated follicular atresia (27).  368 
 369 
Many observational studies have suggested improved ovarian response and pregnancy 370 
outcomes after DHEA supplementation in poor responders (2, 4, 5, 7, 28-33). Wiser et al 371 
conducted a RCT and concluded that DHEA could lead to significantly improved live birth 372 
rate among poor responders undergoing IVF treatment (11). However, there was no priori 373 
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sample size calculation, and concluding a significant improvement in live-birth rate by 374 
pooling the results from two treatment cycles with a p-value of 0.05 had been criticized. 375 
Our present study aimed at addressing the uncertain benefit(s) of DHEA in poor responders 376 
undergoing IVF treatment.  377 
 378 
To the best of our knowledge, this is the first RCT that included the comprehensive serum 379 
and follicular fluid hormonal profiles and changes in ovarian response markers in poor 380 
responders throughout the DHEA pretreatment. Serum DHEA-S and total testosterone 381 
levels were significantly higher in the DHEA group starting from week 4. Together with 382 
the significantly lower SHBG, women were exposed to a much higher concentration of 383 
bioavailable free testosterone. After 12 weeks of DHEA, significantly higher follicular 384 
DHEA-S level was achieved. It confirmed the hypothesis that oral DHEA supplementation 385 
for 12 weeks leads to significantly higher intra-ovarian DHEA-S.  386 
 387 
It has been reported that testosterone levels decline with advancing female age and is lower 388 
in women with premature ovarian aging (34). Previous non-randomized study suggested 389 
that lower functional ovarian reserve is an androgen deficient condition and androgen 390 
supplementation should be given to improve functional ovarian reserve(35). In our study, 391 
oral supplementation with DHEA for 12 weeks did manage to significantly increase the 392 
systemic DHEA-S and testosterone levels, as well as the local follicular DHEA-S. 393 
However, significant improvement of various ovarian response markers including AFC, 394 
AMH and FSH reported in previous uncontrolled studies (33, 36) cannot be replicated here.    395 
 396 
Androgen treatment during follicular recruitment has been shown to increase the number of 397 
healthy follicles on morphological assessment in an animal study, despite similar total 398 
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number (37). Clinically, significant reduction in the number of aneuploid embryos after 399 
DHEA supplementation has been reported (38). In our present study, significantly higher 400 
number of TQE was found in subgroup of women having higher follicular DHEA-S but not 401 
in the group randomized to receive DHEA. It suggested that women with higher intra-402 
ovarian DHEA-S, either naturally or achieved through DHEA supplementation, may have 403 
better embryos quality. It is possible that DHEA supplementation may improve the ovarian 404 
environment where follicular maturation takes place leading to reduced aneuploidy (38), 405 
although the underlying mechanism is not known. No significant differences were detected 406 
in terms of the gonadotrophin use or pregnancy outcomes between the two groups. 407 
However, it should be aware that our study was not powered to detect such a difference and 408 
a much larger sample size would be required to confirm or refute such observation.  409 
 410 
It has been proposed that DHEA helps in regulating follicular development through 411 
increased IGF-1 in primate (2, 23). It increases the number of primary, preantral and antral 412 
follicles by increasing the follicular recruitment and initiation together with reduced 413 
follicular atresia, resulting in an increase in the FSH-sensitive growing pool. However, we 414 
did not detect any difference in either serum or follicular IGF-1 levels between the two 415 
groups. It is unlikely that DHEA exerts major effects on follicular development through 416 
IGF-1 in humans. 417 
 418 
One of the major strengths of our study is the double-blinded randomized study design that 419 
minimized potential bias. We have also provided comprehensive data on monthly 420 
ultrasonographic and serum hormonal profiles to detect any changes in ovarian response 421 
markers; subjected all women to a low dose ovarian stimulation as a standardized test of 422 
ovarian response; followed by a IVF treatment cycle under a standard protocol to provide 423 
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clinical outcomes and allowed comparison of the follicular hormonal milieu. These created 424 
a complete picture on the possible effects of DHEA in poor responders.  425 
 426 
Our study is not without limitations. Live-birth rate should be the ideal outcome measure in 427 
clinical trials assessing fertility outcomes. However, current belief in the potential benefit 428 
of DHEA in poor responders was based on the assumption that DHEA increases intra-429 
ovarian androgen concentrations, which in turn improves the functional ovarian reserve, 430 
and ultimately the pregnancy rates. The primary aim of our study was to assess whether 431 
DHEA supplementation would indeed improve the functional ovarian reserve as the logical 432 
first step. AFC was chosen to be the primary outcome measure since it has been widely 433 
accepted as a marker for functional ovarian reserve and is a good predictor of ovarian 434 
response. Compared to other single ovarian response markers, the predictive performance 435 
of AFC towards poor response has been shown to be significantly better than that of basal 436 
FSH (16) and is comparable to AMH (17, 18) or multivariate models (18, 19) in 437 
metaanalyses. If significant improvement can be detected, further RCT could be performed 438 
using the live-birth rate as the primary outcome. Another limitation of our study is the 439 
relatively small sample size. Priori sample size calculation had been performed to ensure 440 
adequate power in assessing the primary outcome. However, the lack of significant 441 
differences especially in the secondary outcomes and/or in subgroup analyses may be 442 
limited by the sample size. Interpretation of these results has to be dealt with cautions.   443 
 444 
Use of pre-treatment DHEA in poor responders had drawn much attention and increasing 445 
number of studies has been performed to assess its efficacy. Majority of the published 446 
studies used DHEA at 25mg 3 times per day for 5 to 16 weeks (11, 36). So far there is no 447 
good data to indicate the optimal duration of DHEA pre-treatment. In the present study, we 448 
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prescribed a 12-week pretreatment based on our published data on the use of DHEA in 449 
women with primary ovarian insufficiency who started to show some improvements in 450 
AFC and/or have growing follicles after 12 weeks of DHEA(14). Currently there has not 451 
been any dose-finding study to confirm the optimal dose and duration for DHEA 452 
supplementation and there is no available data to show the effective serum and/follicular 453 
DHEA-s or testosterone levels achieved from different DHEA regimens. It is possible that 454 
DHEA pre-treatment given at the present dosage and duration may not be adequate to 455 
achieve optimal intra-ovarian androgen levels in all women in order to improve the ovarian 456 
response and outcomes. Further studies may focus on the dose and duration of DHEA used 457 
prior to IVF treatment. 458 
 459 
At the time when our study was started, there was no uniform definition of “poor 460 
responders”. We used AFC <5 as a surrogate marker to predict poor ovarian response since 461 
it has been the widely accepted and adopted criteria (39-41). To compare our population 462 
against the Bologna criteria, all subjects fulfilled the criteria for abnormal ORT. 14 out of 463 
36 of our subjects had previous IVF treatment. The median number of oocyte retrieved was 464 
4 with a mean of 3.79 +/- SD 1.311. Although it does not strictly fit in the ESHRE 465 
consensus Bologna criteria (2011) of </=3 oocyte retrieved, it is compatible with most 466 
published studies which used </=4-5 oocytes as the definition of poor response (42-45) We 467 
exclude women over 40 and those who had previous oophorectomy or ovarian cystectomy, 468 
cytotoxic chemotherapy or pelvic irradiation from our present study to achieve a more 469 
homogenous population for comparison.  470 
 471 
Currently a number of trials are underway to investigate the potential effects of DHEA on 472 
the ovarian response, embryo quality and pregnancy rates (http://clinicaltrials.gov). Further 473 
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studies should employ the definition of poor responders based on the Bologna criteria (46) 474 
to allow meaningful evaluation and meta-analysis of smaller studies.  475 
 476 
Conclusion 477 
No significant improvement in ovarian response markers, ovarian response to a standard 478 
low dose of gonadotrophin stimulation and number of oocytes obtained were detected in 479 
anticipated poor responders receiving 12 weeks of DHEA supplementation prior to the start 480 
IVF treatment compared to placebo. Further RCTs on the use of DHEA in poor responders 481 
should employ the Bologna criteria in defining poor responders and include the delineation 482 
of the optimal regimen. 483 
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Figure legends  645 
 646 
Figure 1a. Box-and-whisker plots of ovarian response markers (AFC, AMH, FSH), serum 647 
estradiol (E2), DHEA-S, testosterone, SHBG and FAI for women randomized into DHEA 648 
(shaded box) and placebo (open box) groups.  649 
Boxes indicate 25th and 75th percentiles, with the horizontal line representing the median 650 
values. Whiskers span the range between the 5th and the 95th percentiles of the data. The x-651 
axis represents the time of the blood taking after DHEA/placebo use. Statistically 652 
significant differences are defined as P < 0.05 and are indicated by an asterisk 653 
FAI – free androgen index, defined as total testosterone /SHBG (both in nmol/L) x 100 654 
Fig 2. Box-and-whisker plots of follicular fluid hormone concentrations for women 655 
randomized into DHEA (shaded box) and placebo (open box) groups. Boxes indicate 25th 656 
and 75th percentiles, with the horizontal line representing the median values. Whiskers span 657 
the range between the 5th and the 95th percentiles of the data. Statistically significant 658 
differences are defined as P < 0.05 and is indicated by an asterisk.  659 
 660 
Supplemental Figure 1. CONSORT 2010 Flow Diagram 661 
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